Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Exelixis |
---|---|
Information provided by: | Exelixis |
ClinicalTrials.gov Identifier: | NCT00336765 |
The purpose of this study is to assess the safety and tolerability of the multiple receptor tyrosine kinase (RTK) inhibitor (including EGFR, VEGFR2, ErbB2, and EphB4) XL647 when given orally daily to adults with advanced solid tumors.
Condition | Intervention | Phase |
---|---|---|
Cancer |
Drug: XL647 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL647 Administered Orally Daily to Subjects With Solid Tumors |
Estimated Enrollment: | 30 |
Study Start Date: | July 2006 |
Estimated Study Completion Date: | December 2007 |
Estimated Primary Completion Date: | December 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: XL647
Tablets supplied in 50-mg strengths administered orally daily
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
Stanford University Medical Center | |
Stanford, California, United States, 94305 | |
United States, Minnesota | |
Mayo Clinic | |
Rochester, Minnesota, United States, 55905 |
Responsible Party: | Exelixis, Inc. ( Harold Keer, MD/Vice President, Clinical Research ) |
Study ID Numbers: | XL647-002 |
Study First Received: | June 12, 2006 |
Last Updated: | June 18, 2008 |
ClinicalTrials.gov Identifier: | NCT00336765 |
Health Authority: | United States: Food and Drug Administration |
solid tumors |